Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement.
Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, Eng P, Niggemann B, Nieto A, Valovirta E, Eigenmann PA, Pajno G, Bufe A, Halken S, Beyer K, Wahn U; European Academy of Allergy and Clinical Immunology. Calderon MA, et al. Among authors: kopp mv. Pediatr Allergy Immunol. 2012 Jun;23(4):300-6. doi: 10.1111/j.1399-3038.2012.01313.x. Pediatr Allergy Immunol. 2012. PMID: 22594930 Review.
A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B. Rolinck-Werninghaus C, et al. Among authors: kopp mv. Allergy. 2004 Dec;59(12):1285-93. doi: 10.1111/j.1398-9995.2004.00627.x. Allergy. 2004. PMID: 15507097 Clinical Trial.
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group. Kopp MV, et al. Clin Exp Allergy. 2009 Feb;39(2):271-9. doi: 10.1111/j.1365-2222.2008.03121.x. Epub 2008 Oct 30. Clin Exp Allergy. 2009. PMID: 19016798 Clinical Trial.
S3-Guideline on allergy prevention: 2014 update: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Society for Pediatric and Adolescent Medicine (DGKJ).
Schäfer T, Bauer CP, Beyer K, Bufe A, Friedrichs F, Gieler U, Gronke G, Hamelmann E, Hellermann M, Kleinheinz A, Klimek L, Koletzko S, Kopp M, Lau S, Müsken H, Reese I, Schmidt S, Schnadt S, Sitter H, Strömer K, Vagts J, Vogelberg C, Wahn U, Werfel T, Worm M, Muche-Borowski C. Schäfer T, et al. Allergo J Int. 2014;23(6):186-199. doi: 10.1007/s40629-014-0022-4. Allergo J Int. 2014. PMID: 26120530 Free PMC article.
Perspectives in allergen immunotherapy: 2017 and beyond.
Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, Kleine-Tebbe J, Klimek L, Klysner S, Kopp MV, Kuna P, Larché M, Muraro A, Schmidt-Weber CB, Shamji MH, Simonsen K, Somoza C, Valovirta E, Zieglmayer P, Zuberbier T, Wahn U; FASIT group. Pfaar O, et al. Among authors: kopp mv. Allergy. 2018 Jan;73 Suppl 104:5-23. doi: 10.1111/all.13355. Allergy. 2018. PMID: 29171712 Free article. Review.
Perspectives in allergen immunotherapy: 2019 and beyond.
Pfaar O, Agache I, de Blay F, Bonini S, Chaker AM, Durham SR, Gawlik R, Hellings PW, Jutel M, Kleine-Tebbe J, Klimek L, Kopp MV, Nandy A, Rabin RL, van Ree R, Renz H, Roberts G, Salapatek AM, Schmidt-Weber CB, Shamji MH, Sturm GJ, Virchow JC, Wahn U, Willers C, Zieglmayer P, Akdis CA. Pfaar O, et al. Among authors: kopp mv. Allergy. 2019 Dec;74 Suppl 108:3-25. doi: 10.1111/all.14077. Allergy. 2019. PMID: 31872476 Review.
137 results